TMT PROFILING ANALYSIS - Quantitative proteomic an
ID: 75N92024Q1117Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NHLBIBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Original Source

https://sam.gov/opp/556e486649474a34ace8e83b50f9ccdb/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a federal contract focused on TMT Profiling Analysis, which involves quantitative proteomic analysis of paired FBXW7-mutant and FBXW7-wildtype endometrial cancer cell lines. This procurement aims to advance research in the field of cancer biology by providing critical insights into the proteomic differences between these cell lines. The selected contractor will play a vital role in enhancing the understanding of endometrial cancer, which is essential for developing targeted therapies. Interested parties should contact Ethan Mueller at ethan.mueller@nih.gov for further details regarding the solicitation process.

    Point(s) of Contact
    Mueller, Ethan
    ethan.mueller@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    TMT PROFILING ANALYSIS - Quantitative proteomic an
    Currently viewing
    Solicitation
    Similar Opportunities
    CRO Support for NCATS Bioanalytical Method Development for Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified contractors to provide support for bioanalytical method development for biologics under a Sources Sought notice. The primary objective is to identify capable organizations that can develop and validate bioanalytical methods for quantitative analyses of novel therapeutic biologics and anti-drug antibodies in various biological matrices, as well as manage project administration and quality assurance. This initiative is crucial for advancing drug development processes and ensuring compliance with regulatory standards, ultimately facilitating the transition of therapeutic candidates to clinical trials. Interested parties must submit their capability statements and relevant information by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov.
    Scientific Management and Support to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (NRGR)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for scientific management and support services for the National Institute of Mental Health Repository and Genomics Resource (NRGR). The objective of this procurement is to sustain, enhance, and enrich the NRGR, which provides critical biospecimens and genomic data for research on psychiatric disorders, thereby facilitating a deeper understanding of the genetic factors associated with mental health. This initiative is vital for advancing research in the genetics of mental disorders and ensuring broad access to valuable biospecimens and data resources for the scientific community. Proposals are due by November 8, 2024, and must be submitted electronically via the NIH's eCPS system; interested parties should contact Sarah Adan at sarah.adan@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Control (CMC) services related to the development of drug substances under RFP number 75N95024R00094. The primary objective is to secure high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, ensuring compliance with current Good Manufacturing Practices (cGMP) and federal regulations. This initiative is crucial for advancing therapeutic innovations and facilitating collaborations in drug development, with a total funding amount of up to $49.7 million over the contract period from September 1, 2025, to May 14, 2031. Interested parties must submit their proposals by December 3, 2024, and can direct inquiries to primary contact Samson Shifaraw at samson.shifaraw@nih.gov or secondary contact Valerie Whipple at valerie.whipple@nih.gov.
    A--NIH NeuroBioBank Brain and Tissue Repository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the establishment of the NIH NeuroBioBank Brain and Tissue Repository under Request for Proposal (RFP) No. 75N95024R00124. The objective of this procurement is to create and manage contract collection sites for acquiring, storing, and distributing human brain and central nervous system tissues for research, aimed at advancing the understanding and treatment of nervous system disorders. This initiative is critical for enhancing biomedical research by improving access to well-characterized specimens, thereby supporting scientific investigations into neurological conditions. Proposals are due by November 14, 2024, with the anticipated contract performance period starting on May 1, 2025, and extending through optional years. Interested parties can direct inquiries to Robin D. Knightly at robin.knightly@nih.gov or call +1 301 827 5302 for further information.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.
    Clinical Site and Study Monitoring for NIMH Funded Research in Global Settings
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for clinical site and study monitoring services for research funded by the National Institute of Mental Health (NIMH) in global settings. The primary objective of this procurement is to support efforts aimed at reducing mental health disparities, particularly in low and middle-income countries, through rigorous monitoring practices that comply with federal regulations and Good Clinical Practice. This five-year contract, expected to commence on November 25, 2024, has an anticipated budget of up to $2,000,000, with firm-fixed price task orders awarded as needed. Interested parties should direct inquiries to Cassandra Conley at cassandra.conley@nih.gov or Rieka Plugge at rieka.plugge@nih.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Center for Advancing Translational Sciences (NCATS), is seeking qualified small businesses to provide Chemistry, Manufacturing, and Controls (CMC) and related services for the development of drug products. The objective of this procurement is to support the Therapeutic Development Branch in ensuring the delivery of drug products of sufficient quality and quantity for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic candidates through the drug development pipeline. This opportunity is part of a Small Business Sources Sought notice, aimed at gathering information on the capabilities of small businesses to fulfill these requirements, with a focus on compliance with applicable regulations and the potential for a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract. Interested vendors must submit their capability statements by 10:00 AM Eastern Time on July 21, 2024, to Michelle Cecilia at michelle.cecilia@nih.gov.
    Title: Global Life Sciences Sepax Cell Separation Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed-price contract for the procurement of Global Life Sciences Sepax Cell Separation Kits and Ficoll Paque Premium reagents. The NIH's Department of Transfusion Medicine requires these items to support the manufacturing of cell-based therapies for patients with advanced metastatic cancer, utilizing the Sepax C-Pro Cell Processing Instruments. This acquisition is being conducted under the Simplified Acquisition Procedures, allowing for a sole-source award to Cytiva-Global Life Sciences Solutions USA LLC, with capability statements due by November 3, 2024, at 12:00 PM EST. Interested parties can direct inquiries to Sheri Eiri at sheri.eiri@nih.gov.
    Consulting Services in relation to Medical Device Development under Blueprint MedTech Initiative – Subject Matter Expert in Medical Insurance
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is planning to award a sole-source contract to Dr. Rhonda Robinson Beale for consulting services related to medical device development under the Blueprint MedTech Initiative. The primary objective of this procurement is to secure a subject matter expert with extensive experience in U.S. medical insurance and coverage, who will provide strategic guidance and oversight on various projects within the initiative, which aims to accelerate the development of translational neurological medical devices. The Blueprint MedTech Initiative is crucial for supporting innovators in overcoming challenges in bringing medical technologies from concept to clinical application, with a funding allocation of $32 million from 2019 to 2027 to facilitate at least ten successful clinical studies. Interested parties can reach out to Tracy Cain at tracy.cain@nih.gov or Llakim Dubroff at llakim.dubroff@nih.gov for further information, although the final decision for this contract award will remain at the government's discretion.
    Consulting Services in relation to Medical Device Development under Blueprint MedTech Initiative – Subject Matter Expert in Medical Device Investment
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole-source contract for consulting services related to medical device development under the Blueprint MedTech Initiative. The objective is to procure a subject matter expert with extensive experience in neurotechnology and mental health product development, who will provide technical guidance and strategic oversight as a member of the Blueprint MedTech External Oversight Committee. This initiative, established in 2019 with a budget of $32 million, aims to facilitate the transition of innovative neurotechnologies to clinical studies, addressing the challenges faced by innovators in the medical device sector. Interested parties may express their capabilities, but the decision to proceed with competition remains at the government's discretion. For inquiries, contact Tracy Cain at tracy.cain@nih.gov or Llakim Dubroff at llakim.dubroff@nih.gov, both reachable at 301-443-6677.